Get the Stockscreener App
0.00
100.00%
-0.365
After Hours:
.38
0.38
+
Elevation Oncology Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon.
See More
Previous Close:
$0.365
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$21.63M
Revenue:
-
Net Income/Loss:
$-41.95M
P/E Ratio:
0.00
EPS:
-0.83
Net Cash Flow:
$-38.34M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$0.98
Elevation Oncology Inc Stock (ELEV) Company Profile
Name
Elevation Oncology Inc
Sector
Industry
Phone
(716) 371-1125
Address
101 FEDERAL STREET, BOSTON
Compare ELEV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELEV
Elevation Oncology Inc
|
0.00 | 21.63M | 0 | -41.95M | -38.34M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.48 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.36 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.12 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
901.17 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.00 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Elevation Oncology Inc Stock (ELEV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-24-25 | Downgrade | Stephens | Overweight → Equal-Weight |
| Mar-21-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Mar-21-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-21-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-03-25 | Initiated | William Blair | Outperform |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| May-14-24 | Initiated | Stephens | Overweight |
| Mar-01-24 | Initiated | JMP Securities | Mkt Outperform |
| May-30-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Dec-23-21 | Initiated | H.C. Wainwright | Buy |
View All
Elevation Oncology Inc Stock (ELEV) Latest News
Breakout Zone: How institutional buying supports Elevation Oncology Inc stock2025 Market Overview & Short-Term Trading Alerts - BỘ NỘI VỤ
What insider trading reveals about Elevation Oncology Inc. stockJuly 2025 Recap & High Accuracy Buy Signal Tips - Newser
Is Elevation Oncology Inc. stock ready for breakoutWeekly Trade Recap & Consistent Income Trade Recommendations - Newser
Elevation Oncology announces CSO departure - MSN
Rare NRG1 Fusion Market Research Report 2025-2035 Featuring Merus, Hummingbird Bioscience, Elevation Oncology (Concentra Biosciences), and Shenzhen Salubris PharmaceuticalsResearchAndMarkets.com - Business Wire
Can Elevation Oncology Inc. stock hit analyst price targetsJuly 2025 Movers & Real-Time Volume Analysis Alerts - newser.com
What margin trends mean for Elevation Oncology Inc. stockTake Profit & Real-Time Chart Breakout Alerts - newser.com
Using data models to predict Elevation Oncology Inc. stock movementJuly 2025 Recap & AI Powered Market Trend Analysis - newser.com
Visualizing Elevation Oncology Inc. stock with heatmapsAnalyst Downgrade & Fast Entry High Yield Stock Tips - newser.com
Predicting Elevation Oncology Inc. trend using moving averagesJuly 2025 Movers & Verified Chart Pattern Trade Signals - newser.com
Is Elevation Oncology Inc. showing signs of accumulationJuly 2025 EndofMonth & Reliable Price Action Trade Plans - newser.com
What’s next for Elevation Oncology Inc. stock priceEntry Point & Safe Capital Growth Trade Ideas - newser.com
Measuring Elevation Oncology Inc.’s beta against major indicesPortfolio Risk Summary & Safe Swing Trade Setup Alerts - newser.com
What Fibonacci levels say about Elevation Oncology Inc. reboundMarket Activity Summary & Technical Pattern Based Buy Signals - newser.com
Can Elevation Oncology Inc. stock sustain market leadershipWeekly Loss Report & Weekly Sector Rotation Insights - newser.com
Will Elevation Oncology Inc. stock split again soonJuly 2025 Levels & Safe Capital Investment Plans - newser.com
Can Elevation Oncology Inc. stock beat analyst upgradesAnalyst Downgrade & Low Drawdown Momentum Ideas - newser.com
What to do if you’re stuck in Elevation Oncology Inc.Market Trend Review & Free Reliable Trade Execution Plans - newser.com
Will Elevation Oncology Inc. stock deliver consistent dividends2025 Buyback Activity & Safe Capital Growth Stock Tips - newser.com
Is Elevation Oncology Inc. stock a contrarian buyJuly 2025 PreEarnings & AI Enhanced Trading Alerts - newser.com
Can Elevation Oncology Inc. stock sustain free cash flow growthJuly 2025 Institutional & Verified Short-Term Plans - newser.com
Why Elevation Oncology Inc. is moving todayJuly 2025 Market Mood & Pattern Based Trade Signal System - newser.com
Why Elevation Oncology Inc. stock is favored by top institutionsVolume Spike & Consistent Return Strategy Ideas - Fundação Cultural do Pará
Elevation Oncology Inc Stock (ELEV) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.44%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):